On June 5, 2025, MoonLake Immunotherapeutics held its Annual General Meeting, where all director nominees were elected, and proposals for auditor ratification and executive compensation advisory vote were approved. The meeting had 63,474,253 Class A and 729,320 Class C shares eligible to vote.